Creutzfeldt-Jakob disease and plasma-derived and urine-derived medicinal products

Current version

PDF iconRevision 2 - Position statement

Reference number CHMP/BWP/303353/2010
Published 28/06/2011
Keywords Creutzfeldt-Jakob disease, human transmissible spongiform encephalopathies, plasma-derived medicinal products, urine-derived medicinal products, sporadic CJD, genetic CJD, iatrogenic CJD, variant CJD, blood infectivity, transmissibility
Description This document addresses the safety of plasma-derived and urine-derived medicinal products with respect to Creutzfeldt-Jakob disease (CJD). It gives special consideration to variant Creutzfeldt-Jakob disease (vCJD) infectivity.


Document history

Revision 2

Current version

PDF iconPosition statement

 

PDF iconOverview of comments

 

PDF iconDraft position statement

 

PDF iconConcept paper

Published: 28/06/2011

 

Published: 28/06/2011

 

Published: 27/07/2010

 

Published: 23/07/2009

Revision 1 PDF iconPosition statement Published: 23/06/2004
First version PDF iconPosition statement Published: 20/02/2003
Superseded document PDF iconPosition statement Published: 25/02/1998


Related content


How useful was this page?

Add your rating